REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Wednesday, March 13, 2024, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI41e6b8f8ab024eefafe43493f6fd0cdf
Webcast: https://edge.media-server.com/mmc/p/7c7bss7i
The press release with the fourth quarter and full year 2023 financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information
Investors:
Jami Taylor, Head of Investor Relations for Coherus
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.20 |
| Daily Change: | -0.03 -2.44 |
| Daily Volume: | 2,030,828 |
| Market Cap: | US$145.040M |
November 07, 2025 November 06, 2025 November 06, 2025 August 07, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load